Initiator Pharma A/S (INIT) - Total Assets
Based on the latest financial reports, Initiator Pharma A/S (INIT) holds total assets worth Skr36.84 Million SEK (≈ $3.96 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Initiator Pharma A/S (INIT) shareholders funds for net asset value and shareholders' equity analysis.
Initiator Pharma A/S - Total Assets Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's total assets have evolved over time, based on quarterly financial data.
Initiator Pharma A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Initiator Pharma A/S's total assets of Skr36.84 Million consist of 99.9% current assets and 0.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 87.4% |
| Accounts Receivable | Skr0.00 | 0.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr0.00 | 0.0% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see INIT stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Initiator Pharma A/S's current assets represent 99.9% of total assets in 2024, an increase from 70.7% in 2016.
- Cash Position: Cash and equivalents constituted 87.4% of total assets in 2024, up from 29.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 17.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Initiator Pharma A/S Competitors by Total Assets
Key competitors of Initiator Pharma A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Initiator Pharma A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 16.53 | 11.79 | 13.06 |
| Quick Ratio | 16.53 | 11.79 | 13.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr34.59 Million | Skr15.73 Million | Skr14.40 Million |
Initiator Pharma A/S - Advanced Valuation Insights
This section examines the relationship between Initiator Pharma A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.44 |
| Latest Market Cap to Assets Ratio | 1.58 |
| Asset Growth Rate (YoY) | -48.7% |
| Total Assets | Skr15.29 Million |
| Market Capitalization | $24.16 Million USD |
Valuation Analysis
Above Book Valuation: The market values Initiator Pharma A/S's assets above their book value (1.58x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Initiator Pharma A/S's assets decreased by 48.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Initiator Pharma A/S (2016–2024)
The table below shows the annual total assets of Initiator Pharma A/S from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr15.29 Million ≈ $1.65 Million |
-48.66% |
| 2023-12-31 | Skr29.79 Million ≈ $3.21 Million |
-38.39% |
| 2022-12-31 | Skr48.34 Million ≈ $5.20 Million |
-9.97% |
| 2021-12-31 | Skr53.70 Million ≈ $5.78 Million |
+244.17% |
| 2020-12-31 | Skr15.60 Million ≈ $1.68 Million |
+36.41% |
| 2019-12-31 | Skr11.44 Million ≈ $1.23 Million |
-33.99% |
| 2018-12-31 | Skr17.33 Million ≈ $1.86 Million |
+86.36% |
| 2017-12-31 | Skr9.30 Million ≈ $1.00 Million |
+1551.51% |
| 2016-12-31 | Skr563.00K ≈ $60.59K |
-- |
About Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more